Riskpilot← Back to searchSign inGet full accessOxyton AB
ABActiveOrg 5569387474Ekstigen 12 BHospital activities · NACE 8610Est. 20130 employees
Revenue 2024
SEK 288K
-17% vs 2023
EBITDA margin
78.4%
+583% vs 2023
Equity ratio
88.7%
Financial strength
Net profit 2024
SEK 272K
+665% vs 2023
| Revenue | SEK 288K | -17% |
| EBITDA | SEK 226K | +583% |
| Net profit | SEK 272K | +665% |
| Total assets | SEK 599K | -5% |
| Equity | SEK 532K | +105% |
| Employees | 0 | — |
Legal name
Oxyton AB
Org number
5569387474
Legal form
Aktiebolag
NACE code
8610 · Hospital activities
Founded
7 augusti 2013
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Specialistläkarvård, företrädesvis inom anestesi- och intensivvård, prehospital medicin och pedriatrik, med patientkontakt. Ledning och utbildning inom sjukvårdsverksamhet, ej patient- kontakt. Datakonsultverksamhet inom hälso- och sjukvård. Forskningskonsultverksamhet inom hälso- och sjukvård. Produktion och distribution av CD och DVD-media. Artistverksamhet och förmedling.
Address
Ekstigen 12 B
Email
johan@oxyton.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 408 | 375 | 484 | 345 | 288 |
| Staff expenses | — | — | −254 | −68 | 198 |
| EBITDA | 54 | −111 | −34 | 33 | 226 |
| Depreciation & amort. | −20 | −15 | −19 | −21 | −23 |
| EBIT | 34 | −126 | −53 | 12 | 202 |
| Net financials | −28 | −99 | −20 | 23 | 70 |
| Profit before tax | 20 | −26 | −73 | 36 | 272 |
| Tax | −0 | −0 | — | — | — |
| Net profit | 20 | −26 | −73 | 36 | 272 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 703 | 744 | 730 | 632 | 599 |
| Equity | 323 | 297 | 224 | 259 | 532 |
| Long-term debt | 0 | 0 | — | — | — |
| Short-term debt | 77 | 88 | 122 | 65 | 68 |
| Total debt | 77 | 88 | 122 | 65 | 68 |
EBITDA margin
78.4%
This company
15.8%
Market median
+396% vs market
20202024
Equity ratio
88.7%
This company
38.2%
Market median
+132% vs market
20202024
Return on equity
51.2%
This company
18.4%
Market median
+178% vs market
20202024
Net profit margin
94.6%
This company
8.1%
Market median
+1068% vs market
20202024
Asset turnover
0.48×
This company
1.12×
Market median
-57% vs market
20202024
Debt / equity
0.13×
This company
0.62×
Market median
+79% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
KA Deputy Chief Executive Officer | Deputy Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Deputy Board Member | 2022 | |
| Chairman | 2022 | |
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Oxyton AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Karin Agneta Uusijärvi | Deputy Chief Executive Officer | 0 companies |
| Albin Åke Uusijärvi | Deputy Board Member | 0 companies |
| Per Johan Uusijärvi | Chairman | 0 companies |
| Per Erik Uusijärvi | Deputy Board Member | 0 companies |